{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:10:06Z","timestamp":1783609806403,"version":"3.55.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Parasit."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11686-025-01161-5","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:56:30Z","timestamp":1763139390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic Manipulation Tools in Leishmania: From CRISPR\/Cas9 to Vaccine Strategies for Disease Control"],"prefix":"10.1007","volume":"70","author":[{"given":"Merve","family":"Gundogdu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Islek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"1161_CR1","unstructured":"World Health Organization (2024) Leishmaniasis. In: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis"},{"key":"1161_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/DDDT.S146521","volume":"12","author":"M Ghorbani","year":"2017","unstructured":"Ghorbani M, Farhoudi R (2017) Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther 12:25\u201340. https:\/\/doi.org\/10.2147\/DDDT.S146521","journal-title":"Drug Des Devel Ther"},{"key":"1161_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13071-017-2028-5","volume":"10","author":"D Steverding","year":"2017","unstructured":"Steverding D (2017) The history of leishmaniasis. Parasit Vectors 10:82. https:\/\/doi.org\/10.1186\/s13071-017-2028-5","journal-title":"Parasit Vectors"},{"key":"1161_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.958693","author":"E Due\u00f1as","year":"2022","unstructured":"Due\u00f1as E, Nakamoto JA, Cabrera-Sosa L et al (2022) Novel CRISPR-based detection of Leishmania species. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2022.958693","journal-title":"Front Microbiol"},{"key":"1161_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J, V\u00e9lez ID, Bern C et al (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7:e35671. https:\/\/doi.org\/10.1371\/journal.pone.0035671","journal-title":"PLoS ONE"},{"key":"1161_CR6","doi-asserted-by":"publisher","unstructured":"Islek Z, Ucisik MH, Keskin E, et al (2022) Antileishmanial Activity of BNIPDaoct- and BNIPDanon-loaded emulsomes on Leishmania infantum parasites. Front Nanotechnol 3. https:\/\/doi.org\/10.3389\/fnano.2021.773741","DOI":"10.3389\/fnano.2021.773741"},{"key":"1161_CR7","doi-asserted-by":"crossref","unstructured":"Islek Z, Turhan Bozkurt B, Hikmet Ucisik M, Sahin F (2022) The role of extracellular vesicles in \u0131mmunomodulation and pathogenesis of Leishmania and other protozoan \u0131nfections","DOI":"10.5772\/intechopen.101682"},{"key":"1161_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2915.2012.01034.x","volume":"27","author":"M Maroli","year":"2013","unstructured":"Maroli M, Feliciangeli MD, Bichaud L et al (2013) Phlebotomine sandflies and the spreading of leishmaniases and other diseases of public health concern. Med Vet Entomol 27:123\u2013147. https:\/\/doi.org\/10.1111\/j.1365-2915.2012.01034.x","journal-title":"Med Vet Entomol"},{"key":"1161_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s12639-020-01212-w","volume":"44","author":"S Thakur","year":"2020","unstructured":"Thakur S, Joshi J, Kaur S (2020) Leishmaniasis diagnosis: an update on the use of parasitological, immunological and molecular methods. J Parasit Dis 44:253\u2013272. https:\/\/doi.org\/10.1007\/s12639-020-01212-w","journal-title":"J Parasit Dis"},{"key":"1161_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40257-022-00726-8","volume":"23","author":"HJC de Vries","year":"2022","unstructured":"de Vries HJC, Schallig HD (2022) Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments. Am J Clin Dermatol 23:823\u2013840. https:\/\/doi.org\/10.1007\/s40257-022-00726-8","journal-title":"Am J Clin Dermatol"},{"key":"1161_CR11","unstructured":"World Health Organization (2024) Leishmaniasis. In: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasiss. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis"},{"key":"1161_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.adengl.2021.05.011","volume":"112","author":"I Abad\u00edas-Granado","year":"2021","unstructured":"Abad\u00edas-Granado I, Diago A, Cerro PA et al (2021) Cutaneous and mucocutaneous leishmaniasis. Actas Dermo-Sifiliogr\u00e1ficas (English Edition) 112:601\u2013618. https:\/\/doi.org\/10.1016\/j.adengl.2021.05.011","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"1161_CR13","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3390\/microorganisms10101887","volume":"10","author":"S Scarpini","year":"2022","unstructured":"Scarpini S, Dondi A, Totaro C et al (2022) Visceral leishmaniasis: epidemiology, diagnosis, and treatment regimens in different geographical areas with a focus on pediatrics. Microorganisms 10:1887. https:\/\/doi.org\/10.3390\/microorganisms10101887","journal-title":"Microorganisms"},{"key":"1161_CR14","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3390\/microorganisms8111632","volume":"8","author":"JQ Reim\u00e3o","year":"2020","unstructured":"Reim\u00e3o JQ, Coser EM, Lee MR, Coelho AC (2020) Laboratory diagnosis of cutaneous and visceral leishmaniasis: current and future methods. Microorganisms 8:1632. https:\/\/doi.org\/10.3390\/microorganisms8111632","journal-title":"Microorganisms"},{"key":"1161_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4269\/ajtmh.1998.58.102","volume":"58","author":"A Belli","year":"1998","unstructured":"Belli A, Harris E, Rodriguez B, Aviles H (1998) Simplified polymerase chain reaction detection of new world Leishmania in clinical specimens of cutaneous leishmaniasis. Am J Trop Med Hyg 58:102\u2013109. https:\/\/doi.org\/10.4269\/ajtmh.1998.58.102","journal-title":"Am J Trop Med Hyg"},{"key":"1161_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13071-018-2859-8","volume":"11","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Ceccarelli M, Diotallevi A et al (2018) Real-time PCR applications for diagnosis of leishmaniasis. Parasit Vectors 11:273. https:\/\/doi.org\/10.1186\/s13071-018-2859-8","journal-title":"Parasit Vectors"},{"key":"1161_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/505134","volume":"2014","author":"B Sarkari","year":"2014","unstructured":"Sarkari B, Ashrafmansouri M, Hatam G et al (2014) Performance of an ELISA and indirect immunofluorescence assay in serological diagnosis of zoonotic cutaneous leishmaniasis in Iran. Interdiscip Perspect Infect Dis 2014:1\u20134. https:\/\/doi.org\/10.1155\/2014\/505134","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"1161_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s13071-022-05524-z","volume":"15","author":"I Gow","year":"2022","unstructured":"Gow I, Smith NC, Stark D, Ellis J (2022) Laboratory diagnostics for human Leishmania infections: a polymerase chain reaction-focussed review of detection and identification methods. Parasit Vectors 15:412. https:\/\/doi.org\/10.1186\/s13071-022-05524-z","journal-title":"Parasit Vectors"},{"key":"1161_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","volume":"96","author":"N Aronson","year":"2017","unstructured":"Aronson N, Herwaldt BL, Libman M et al (2017) Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH). Am J Trop Med Hyg 96:24\u201345. https:\/\/doi.org\/10.4269\/ajtmh.16-84256","journal-title":"Am J Trop Med Hyg"},{"key":"1161_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/cid\/ciy891","volume":"69","author":"D Mondal","year":"2019","unstructured":"Mondal D, Bern C, Ghosh D et al (2019) Quantifying the infectiousness of Post-Kala-Azar dermal leishmaniasis toward sand flies. Clin Infect Dis 69:251\u2013258. https:\/\/doi.org\/10.1093\/cid\/ciy891","journal-title":"Clin Infect Dis"},{"key":"1161_CR21","unstructured":"Tavares J (2008) Antileishmanial drugs: Search for SIR2 inhibitors. Faculty Pharmacy of Porto University"},{"key":"1161_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s40506-015-0038-4","volume":"7","author":"DP Eiras","year":"2015","unstructured":"Eiras DP, Kirkman LA, Murray HW (2015) Cutaneous leishmaniasis: current treatment practices in the USA for returning travelers. Curr Treat Options Infect Dis 7:52\u201362. https:\/\/doi.org\/10.1007\/s40506-015-0038-4","journal-title":"Curr Treat Options Infect Dis"},{"key":"1161_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1017\/S0031182016002523","volume":"145","author":"SRB Uliana","year":"2018","unstructured":"Uliana SRB, Trinconi CT, Coelho AC (2018) Chemotherapy of leishmaniasis: present challenges. Parasitology 145:464\u2013480. https:\/\/doi.org\/10.1017\/S0031182016002523","journal-title":"Parasitology"},{"key":"1161_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12879-016-1663-3","volume":"16","author":"L L\u00f3pez-Carvajal","year":"2016","unstructured":"L\u00f3pez-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI et al (2016) Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infect Dis 16:360. https:\/\/doi.org\/10.1186\/s12879-016-1663-3","journal-title":"BMC Infect Dis"},{"key":"1161_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1590\/abd1806-4841.20186415","volume":"93","author":"SVCB Gon\u00e7alves","year":"2018","unstructured":"Gon\u00e7alves SVCB, Costa CHN (2018) Treatment of cutaneous leishmaniasis with thermotherapy in Brazil: an efficacy and safety study. An Bras Dermatol 93:347\u2013355. https:\/\/doi.org\/10.1590\/abd1806-4841.20186415","journal-title":"An Bras Dermatol"},{"key":"1161_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s10103-020-03006-1","volume":"35","author":"AH Siadat","year":"2020","unstructured":"Siadat AH, Zolfaghari A, Shahmoradi Z et al (2020) Application of laser for treatment of cutaneous leishmaniasis: a review of literature. Lasers Med Sci 35:1451\u20131457. https:\/\/doi.org\/10.1007\/s10103-020-03006-1","journal-title":"Lasers Med Sci"},{"key":"1161_CR27","doi-asserted-by":"crossref","unstructured":"Oliveira RM de, Melo S de A, Penha-Silva TA da, et al (2018) Alternative treatment for Leishmaniasis. In: Leishmaniases as re-emerging diseases. InTech","DOI":"10.5772\/intechopen.75895"},{"key":"1161_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40121-022-00602-2","volume":"11","author":"RK Madusanka","year":"2022","unstructured":"Madusanka RK, Silva H, Karunaweera ND (2022) Treatment of cutaneous leishmaniasis and insights into species-specific responses: a narrative review. Infect Dis Ther 11:695\u2013711. https:\/\/doi.org\/10.1007\/s40121-022-00602-2","journal-title":"Infect Dis Ther"},{"key":"1161_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/0974-777X.62883","volume":"2","author":"E Moore","year":"2010","unstructured":"Moore E, Lockwood D (2010) Treatment of visceral leishmaniasis. J Glob Infect Dis 2:151. https:\/\/doi.org\/10.4103\/0974-777X.62883","journal-title":"J Glob Infect Dis"},{"key":"1161_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006527","volume":"12","author":"C Abongomera","year":"2018","unstructured":"Abongomera C, Diro E, de Lima Pereira A et al (2018) The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: a retrospective cohort study. PLoS Negl Trop Dis 12:e0006527. https:\/\/doi.org\/10.1371\/journal.pntd.0006527","journal-title":"PLoS Negl Trop Dis"},{"key":"1161_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4103\/0974-777X.62879","volume":"2","author":"E Palumbo","year":"2010","unstructured":"Palumbo E (2010) Treatment strategies for mucocutaneous leishmaniasis. J Glob Infect Dis 2:147. https:\/\/doi.org\/10.4103\/0974-777X.62879","journal-title":"J Glob Infect Dis"},{"key":"1161_CR32","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1016\/j.ijid.2011.03.021","volume":"15","author":"TS Tiuman","year":"2011","unstructured":"Tiuman TS, Santos AO, Ueda-Nakamura T et al (2011) Recent advances in leishmaniasis treatment. Int J Infect Dis 15:e525\u2013e532. https:\/\/doi.org\/10.1016\/j.ijid.2011.03.021","journal-title":"Int J Infect Dis"},{"key":"1161_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/labmed\/lmac134","volume":"54","author":"BA Mathison","year":"2023","unstructured":"Mathison BA, Bradley BT (2023) Review of the clinical presentation, pathology, diagnosis, and treatment of leishmaniasis. Lab Med 54:363\u2013371. https:\/\/doi.org\/10.1093\/labmed\/lmac134","journal-title":"Lab Med"},{"key":"1161_CR34","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1086\/322689","volume":"33","author":"J Soto","year":"2001","unstructured":"Soto J, Toledo J, Gutierrez P et al (2001) Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33:e57\u2013e61. https:\/\/doi.org\/10.1086\/322689","journal-title":"Clin Infect Dis"},{"key":"1161_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0035-9203(96)90271-0","volume":"90","author":"CP Thakur","year":"1996","unstructured":"Thakur CP, Pandey AK, Sinha GP et al (1996) Comparison of three treatment regimens with liposomal amphotericin B (AmBisome\u00ae) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 90:319\u2013322. https:\/\/doi.org\/10.1016\/S0035-9203(96)90271-0","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1161_CR36","first-page":"25","volume":"76","author":"JD Berman","year":"1998","unstructured":"Berman JD, Badaro R, Thakur CP et al (1998) Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76:25\u201332","journal-title":"Bull World Health Organ"},{"key":"1161_CR37","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/clinids\/22.6.938","volume":"22","author":"RN Davidson","year":"1996","unstructured":"Davidson RN, di Martino L, Gradoni L et al (1996) Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 22:938\u2013943. https:\/\/doi.org\/10.1093\/clinids\/22.6.938","journal-title":"Clin Infect Dis"},{"key":"1161_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.1016925","author":"P Kumar","year":"2022","unstructured":"Kumar P, Kumar P, Singh N et al (2022) Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis\u2014an updated review. Front Bioeng Biotechnol. https:\/\/doi.org\/10.3389\/fbioe.2022.1016925","journal-title":"Front Bioeng Biotechnol"},{"key":"1161_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/0974-777X.62887","volume":"2","author":"J Chakravarty","year":"2010","unstructured":"Chakravarty J, Sundar S (2010) Drug resistance in leishmaniasis. J Glob Infect Dis 2:167. https:\/\/doi.org\/10.4103\/0974-777X.62887","journal-title":"J Glob Infect Dis"},{"key":"1161_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ijantimicag.2007.01.004","volume":"29","author":"S Natera","year":"2007","unstructured":"Natera S, Machuca C, Padr\u00f3n-Nieves M et al (2007) Leishmania spp.: proficiency of drug-resistant parasites. Int J Antimicrob Agents 29:637\u2013642. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.01.004","journal-title":"Int J Antimicrob Agents"},{"key":"1161_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/10611860701453836","volume":"15","author":"S Gupta","year":"2007","unstructured":"Gupta S, Dube A, Vyas SP (2007) Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target 15:437\u2013444. https:\/\/doi.org\/10.1080\/10611860701453836","journal-title":"J Drug Target"},{"key":"1161_CR42","doi-asserted-by":"publisher","unstructured":"Gupta S, Dube A, P. Vyas S (2012) Development and characterization of amphotericin B loaded solid lipid nanoparticles against experimental visceral Leishmaniasis. Pharm Nanotechnol 1:54\u201367. https:\/\/doi.org\/10.2174\/2211738511301010054","DOI":"10.2174\/2211738511301010054"},{"key":"1161_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"SL Croft","year":"2006","unstructured":"Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111\u2013126. https:\/\/doi.org\/10.1128\/CMR.19.1.111-126.2006","journal-title":"Clin Microbiol Rev"},{"key":"1161_CR44","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","volume":"366","author":"HW Murray","year":"2005","unstructured":"Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366:1561\u20131577. https:\/\/doi.org\/10.1016\/S0140-6736(05)67629-5","journal-title":"Lancet"},{"key":"1161_CR45","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drup.2004.07.002","volume":"7","author":"M Ouellette","year":"2004","unstructured":"Ouellette M, Drummelsmith J, Papadopoulou B (2004) Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 7:257\u2013266. https:\/\/doi.org\/10.1016\/j.drup.2004.07.002","journal-title":"Drug Resist Updat"},{"key":"1161_CR46","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1086\/377542","volume":"37","author":"S Sundar","year":"2003","unstructured":"Sundar S, Jha TK, Thakur CP et al (2003) Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37:800\u2013804. https:\/\/doi.org\/10.1086\/377542","journal-title":"Clin Infect Dis"},{"key":"1161_CR47","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa021556","volume":"347","author":"S Sundar","year":"2002","unstructured":"Sundar S, Jha TK, Thakur CP et al (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347:1739\u20131746. https:\/\/doi.org\/10.1056\/NEJMoa021556","journal-title":"N Engl J Med"},{"key":"1161_CR48","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01018-21","author":"JE Martinez-Hernandez","year":"2021","unstructured":"Martinez-Hernandez JE, Hammoud Z, de Sousa AM et al (2021) Network-based approaches reveal potential therapeutic targets for host-directed antileishmanial therapy driving drug repurposing. Microbiol Spectr. https:\/\/doi.org\/10.1128\/Spectrum.01018-21","journal-title":"Microbiol Spectr"},{"key":"1161_CR49","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.85605","author":"M Engstler","year":"2023","unstructured":"Engstler M, Beneke T (2023) Gene editing and scalable functional genomic screening in Leishmania species using the CRISPR\/Cas9 cytosine base editor toolbox LeishBASEedit. Elife. https:\/\/doi.org\/10.7554\/eLife.85605","journal-title":"Elife"},{"key":"1161_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2023.110661","volume":"115","author":"WM Goes","year":"2023","unstructured":"Goes WM, Brasil CRF, Reis-Cunha JL et al (2023) Complete assembly, annotation of virulence genes and CRISPR editing of the genome of Leishmania amazonensis PH8 strain. Genomics 115:110661. https:\/\/doi.org\/10.1016\/j.ygeno.2023.110661","journal-title":"Genomics"},{"key":"1161_CR51","doi-asserted-by":"crossref","unstructured":"Zhang WW, Lypaczewski P, Matlashewski G (2020) Application of CRISPR\/Cas9-mediated genome editing in Leishmania. pp 199\u2013224","DOI":"10.1007\/978-1-0716-0294-2_14"},{"key":"1161_CR52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molbiopara.2017.06.005","volume":"216","author":"SM Duncan","year":"2017","unstructured":"Duncan SM, Jones NG, Mottram JC (2017) Recent advances in Leishmania reverse genetics: manipulating a manipulative parasite. Mol Biochem Parasitol 216:30\u201338. https:\/\/doi.org\/10.1016\/j.molbiopara.2017.06.005","journal-title":"Mol Biochem Parasitol"},{"key":"1161_CR53","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/microorganisms11041043","volume":"11","author":"POL Moreira","year":"2023","unstructured":"Moreira POL, Nogueira PM, Monte-Neto RL (2023) Next-generation leishmanization: revisiting molecular targets for selecting genetically engineered live-attenuated Leishmania. Microorganisms 11:1043. https:\/\/doi.org\/10.3390\/microorganisms11041043","journal-title":"Microorganisms"},{"key":"1161_CR54","doi-asserted-by":"publisher","first-page":"18501","DOI":"10.1038\/s41598-021-97984-z","volume":"11","author":"T Nishi","year":"2021","unstructured":"Nishi T, Shinzawa N, Yuda M, Iwanaga S (2021) Highly efficient CRISPR\/Cas9 system in Plasmodium falciparum using Cas9-expressing parasites and a linear donor template. Sci Rep 11:18501. https:\/\/doi.org\/10.1038\/s41598-021-97984-z","journal-title":"Sci Rep"},{"key":"1161_CR55","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12639-022-01534-x","volume":"46","author":"S Pal","year":"2022","unstructured":"Pal S, Dam S (2022) CRISPR-Cas9: taming protozoan parasites with bacterial scissor. J Parasit Dis 46:1204\u20131212. https:\/\/doi.org\/10.1007\/s12639-022-01534-x","journal-title":"J Parasit Dis"},{"key":"1161_CR56","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.tibs.2015.08.006","volume":"40","author":"A Sfeir","year":"2015","unstructured":"Sfeir A, Symington LS (2015) Microhomology-mediated end joining: a back-up survival mechanism or dedicated pathway? Trends Biochem Sci 40:701\u2013714. https:\/\/doi.org\/10.1016\/j.tibs.2015.08.006","journal-title":"Trends Biochem Sci"},{"key":"1161_CR57","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00408-19","author":"W-W Zhang","year":"2019","unstructured":"Zhang W-W, Matlashewski G (2019) Single-strand annealing plays a major role in double-strand DNA break repair following CRISPR-Cas9 cleavage in Leishmania. mSphere. https:\/\/doi.org\/10.1128\/mSphere.00408-19","journal-title":"mSphere"},{"key":"1161_CR58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11686-023-00756-0","volume":"69","author":"A Abdi Ghavidel","year":"2024","unstructured":"Abdi Ghavidel A, Aghamiri S, Raee P et al (2024) Recent advances in CRISPR\/Cas9-mediated genome editing in Leishmania strains. Acta Parasitol 69:121\u2013134. https:\/\/doi.org\/10.1007\/s11686-023-00756-0","journal-title":"Acta Parasitol"},{"key":"1161_CR59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1124\/jpet.122.001234","volume":"384","author":"GM Traber","year":"2023","unstructured":"Traber GM, Yu A-M (2023) RNAi-based therapeutics and novel RNA bioengineering technologies. J Pharmacol Exp Ther 384:133\u2013154. https:\/\/doi.org\/10.1124\/jpet.122.001234","journal-title":"J Pharmacol Exp Ther"},{"key":"1161_CR60","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10555-017-9717-6","volume":"37","author":"X Chen","year":"2018","unstructured":"Chen X, Mangala LS, Rodriguez-Aguayo C et al (2018) RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37:107\u2013124. https:\/\/doi.org\/10.1007\/s10555-017-9717-6","journal-title":"Cancer Metastasis Rev"},{"key":"1161_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/genes14010093","volume":"14","author":"L-F Lye","year":"2022","unstructured":"Lye L-F, Owens KL, Jang S et al (2022) An RNA interference (RNAi) toolkit and its utility for functional genetic analysis of Leishmania (Viannia). Genes 14:93. https:\/\/doi.org\/10.3390\/genes14010093","journal-title":"Genes"},{"key":"1161_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","volume":"59","author":"L Aagaard","year":"2007","unstructured":"Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59:75\u201386. https:\/\/doi.org\/10.1016\/j.addr.2007.03.005","journal-title":"Adv Drug Deliv Rev"},{"key":"1161_CR63","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1462-5822.2004.00399.x","volume":"6","author":"E Ullu","year":"2004","unstructured":"Ullu E, Tschudi C, Chakraborty T (2004) RNA interference in protozoan parasites. Cell Microbiol 6:509\u2013519. https:\/\/doi.org\/10.1111\/j.1462-5822.2004.00399.x","journal-title":"Cell Microbiol"},{"key":"1161_CR64","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0166-6851(03)00079-3","volume":"128","author":"KA Robinson","year":"2003","unstructured":"Robinson KA, Beverley SM (2003) Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania. Mol Biochem Parasitol 128:217\u2013228. https:\/\/doi.org\/10.1016\/S0166-6851(03)00079-3","journal-title":"Mol Biochem Parasitol"},{"key":"1161_CR65","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1128\/MCB.24.1.420-427.2004","volume":"24","author":"H Shi","year":"2004","unstructured":"Shi H, Djikeng A, Tschudi C, Ullu E (2004) Argonaute protein in the early divergent eukaryote Trypanosoma brucei: control of small interfering RNA accumulation and retroposon transcript abundance. Mol Cell Biol 24:420\u2013427. https:\/\/doi.org\/10.1128\/MCB.24.1.420-427.2004","journal-title":"Mol Cell Biol"},{"key":"1161_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001161","volume":"6","author":"L-F Lye","year":"2010","unstructured":"Lye L-F, Owens K, Shi H et al (2010) Retention and loss of RNA interference pathways in trypanosomatid protozoans. PLoS Pathog 6:e1001161. https:\/\/doi.org\/10.1371\/journal.ppat.1001161","journal-title":"PLoS Pathog"},{"key":"1161_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13071-016-1553-y","volume":"9","author":"S Srivastava","year":"2016","unstructured":"Srivastava S, Shankar P, Mishra J, Singh S (2016) Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasit Vectors 9:277. https:\/\/doi.org\/10.1186\/s13071-016-1553-y","journal-title":"Parasit Vectors"},{"key":"1161_CR68","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/ng2053","volume":"39","author":"CS Peacock","year":"2007","unstructured":"Peacock CS, Seeger K, Harris D et al (2007) Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet 39:839\u2013847. https:\/\/doi.org\/10.1038\/ng2053","journal-title":"Nat Genet"},{"key":"1161_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1182141","author":"B Vom\u00e1\u010dkov\u00e1 Kykalov\u00e1","year":"2023","unstructured":"Vom\u00e1\u010dkov\u00e1 Kykalov\u00e1 B, Sass\u00f9 F, Volf P, Telleria EL (2023) RNAi-mediated gene silencing of Phlebotomus papatasi defensins favors Leishmania major infection. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2023.1182141","journal-title":"Front Physiol"},{"key":"1161_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1287539","author":"A Moradimotlagh","year":"2023","unstructured":"Moradimotlagh A, Chen S, Koohbor S et al (2023) Leishmania infection upregulates and engages host macrophage Argonaute 1, and system-wide proteomics reveals Argonaute 1-dependent host response. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1287539","journal-title":"Front Immunol"},{"key":"1161_CR71","first-page":"377","volume":"76","author":"A Nadim","year":"1983","unstructured":"Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M (1983) Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Fil 76:377\u2013383","journal-title":"Bull Soc Pathol Exot Fil"},{"key":"1161_CR72","doi-asserted-by":"publisher","unstructured":"Das A, Ali N (2012) Vaccine development against leishmania donovani. Front Immunol 3. https:\/\/doi.org\/10.3389\/fimmu.2012.00099","DOI":"10.3389\/fimmu.2012.00099"},{"key":"1161_CR73","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0304-4017(01)00486-1","volume":"100","author":"L Gradoni","year":"2001","unstructured":"Gradoni L (2001) An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol 100:87\u2013103. https:\/\/doi.org\/10.1016\/S0304-4017(01)00486-1","journal-title":"Vet Parasitol"},{"key":"1161_CR74","doi-asserted-by":"publisher","unstructured":"Suman Karmakar, Mousumi Das and Monalisa Ray et al (2024) Prospects and challenges of genetically modified live-attenuated leishmania vaccines. Zoonoses. 4(1). https:\/\/doi.org\/10.15212\/zoonoses-2024-0010","DOI":"10.15212\/zoonoses-2024-0010"},{"key":"1161_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/biohorizons\/hzp004","volume":"2","author":"N Dunning","year":"2009","unstructured":"Dunning N (2009) Leishmania vaccines: from leishmanization to the era of DNA technology. Biosci Horiz 2:73\u201382. https:\/\/doi.org\/10.1093\/biohorizons\/hzp004","journal-title":"Biosci Horiz"},{"key":"1161_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071972","volume":"15","author":"N Al Fayez","year":"2023","unstructured":"Al Fayez N, Nassar MS, Alshehri AA et al (2023) Recent advancement in mRNA vaccine development and applications. Pharmaceutics 15:1972. https:\/\/doi.org\/10.3390\/pharmaceutics15071972","journal-title":"Pharmaceutics"},{"key":"1161_CR77","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3347\/kjp.2022.60.6.379","volume":"60","author":"R Dinc","year":"2022","unstructured":"Dinc R (2022) Leishmania vaccines: the current situation with its promising aspect for the future. Korean J Parasitol 60:379\u2013391. https:\/\/doi.org\/10.3347\/kjp.2022.60.6.379","journal-title":"Korean J Parasitol"},{"issue":"1","key":"1161_CR78","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/immuno2010015","volume":"2","author":"H Yasmin","year":"2022","unstructured":"Yasmin H, Adhikary A, Al-Ahdal MN et al (2022) Host-pathogen interaction in leishmaniasis: immune response and vaccination strategies. Immuno 2(1):218\u2013254. https:\/\/doi.org\/10.3390\/immuno2010015","journal-title":"Immuno"},{"key":"1161_CR79","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1016\/S0264-410X(02)00376-6","volume":"20","author":"S M\u00e9ndez","year":"2002","unstructured":"M\u00e9ndez S, Belkaid Y, Seder RA, Sacks D (2002) Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702\u20133708. https:\/\/doi.org\/10.1016\/S0264-410X(02)00376-6","journal-title":"Vaccine"},{"key":"1161_CR80","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-3024.2009.01111.x","volume":"31","author":"SA Ali","year":"2009","unstructured":"Ali SA, Rezvan H, McArdle SE et al (2009) CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model. Parasite Immunol 31:373\u2013383. https:\/\/doi.org\/10.1111\/j.1365-3024.2009.01111.x","journal-title":"Parasite Immunol"},{"key":"1161_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.54","volume":"1","author":"TR Smith","year":"2014","unstructured":"Smith TR, Schultheis K, Kiosses WB et al (2014) DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Mol Ther 1:14054. https:\/\/doi.org\/10.1038\/mtm.2014.54","journal-title":"Mol Ther"},{"key":"1161_CR82","doi-asserted-by":"publisher","first-page":"19421","DOI":"10.1038\/s41598-023-46408-1","volume":"13","author":"ER Basmenj","year":"2023","unstructured":"Basmenj ER, Arastonejad M, Mamizadeh M et al (2023) Engineering and design of promising T-cell-based multi-epitope vaccine candidates against leishmaniasis. Sci Rep 13:19421. https:\/\/doi.org\/10.1038\/s41598-023-46408-1","journal-title":"Sci Rep"},{"key":"1161_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2023.100403","volume":"15","author":"BLS Costa Souza","year":"2023","unstructured":"Costa Souza BLS, Pinto EF, Bezerra IPS et al (2023) Crosslinked chitosan microparticles as a safe and efficient DNA carrier for intranasal vaccination against cutaneous leishmaniasis. Vaccine X 15:100403. https:\/\/doi.org\/10.1016\/j.jvacx.2023.100403","journal-title":"Vaccine X"},{"key":"1161_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005527","volume":"11","author":"M Osman","year":"2017","unstructured":"Osman M, Mistry A, Keding A et al (2017) A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis 11:e0005527. https:\/\/doi.org\/10.1371\/journal.pntd.0005527","journal-title":"PLoS Negl Trop Dis"},{"key":"1161_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512334","volume":"24","author":"A Mas","year":"2023","unstructured":"Mas A, Hurtado-Morillas C, Mart\u00ednez-Rodrigo A et al (2023) A tailored approach to leishmaniases vaccination: comparative evaluation of the efficacy and cross-protection capacity of DNA vs. peptide-based vaccines in a murine model. Int J Mol Sci 24:12334. https:\/\/doi.org\/10.3390\/ijms241512334","journal-title":"Int J Mol Sci"},{"issue":"5400","key":"1161_CR86","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1016\/j.vaccine.2023.07.020","volume":"41","author":"M de Carvalho Cl\u00edmaco","year":"2023","unstructured":"de Carvalho Cl\u00edmaco M, de Figueiredo LA, Lucas RC et al (2023) Development of chimeric protein as a multivalent vaccine for human kinetoplastid infections: chagas disease and leishmaniasis. Vaccine 41(5400):5411. https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.020","journal-title":"Vaccine"},{"key":"1161_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2023.152725","volume":"228","author":"X Liao","year":"2023","unstructured":"Liao X, He J, Wang R et al (2023) TLR-2 agonist Pam3CSK4 has no therapeutic effect on visceral leishmaniasis in BALB\/c mice and may enhance the pathogenesis of the disease. Immunobiology 228:152725. https:\/\/doi.org\/10.1016\/j.imbio.2023.152725","journal-title":"Immunobiology"},{"key":"1161_CR88","doi-asserted-by":"publisher","first-page":"14912","DOI":"10.1038\/s41598-023-41526-2","volume":"13","author":"M Ghassemi","year":"2023","unstructured":"Ghassemi M, Akhavan AA, Zahraei-Ramazani A et al (2023) Rodents as vehicle for delivery of transgenic bacteria to make paratransgenic sand fly vectors of cutaneous leishmaniasis in field condition. Sci Rep 13:14912. https:\/\/doi.org\/10.1038\/s41598-023-41526-2","journal-title":"Sci Rep"},{"key":"1161_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1259612","author":"S Aiman","year":"2023","unstructured":"Aiman S, Ahmad A, Khan AA et al (2023) Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction against Leishmania tropica - a hierarchical subtractive proteomics and immunoinformatics approach. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1259612","journal-title":"Front Immunol"},{"key":"1161_CR90","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.4155\/cli.13.99","volume":"3","author":"T Taheri","year":"2013","unstructured":"Taheri T, Rafati S (2013) Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development. Clin Investig (Lond) 3:1023\u20131044. https:\/\/doi.org\/10.4155\/cli.13.99","journal-title":"Clin Investig (Lond)"},{"key":"1161_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12762","author":"M Nateghi Rostami","year":"2020","unstructured":"Nateghi Rostami M (2020) CRISPR\/Cas9 gene drive technology to control transmission of vector-borne parasitic infections. Parasite Immunol. https:\/\/doi.org\/10.1111\/pim.12762","journal-title":"Parasite Immunol"},{"key":"1161_CR92","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang F, Doudna JA (2017) CRISPR\u2013Cas9 structures and mechanisms. Annu Rev Biophys 46:505\u2013529. https:\/\/doi.org\/10.1146\/annurev-biophys-062215-010822","journal-title":"Annu Rev Biophys"},{"key":"1161_CR93","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J et al (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281\u20132308. https:\/\/doi.org\/10.1038\/nprot.2013.143","journal-title":"Nat Protoc"},{"key":"1161_CR94","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrmicro3279","volume":"12","author":"J van der Oost","year":"2014","unstructured":"van der Oost J, Westra ER, Jackson RN, Wiedenheft B (2014) Unravelling the structural and mechanistic basis of CRISPR\u2013Cas systems. Nat Rev Microbiol 12:479\u2013492. https:\/\/doi.org\/10.1038\/nrmicro3279","journal-title":"Nat Rev Microbiol"},{"key":"1161_CR95","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","volume":"37","author":"C Xue","year":"2021","unstructured":"Xue C, Greene EC (2021) DNA repair pathway choices in CRISPR-Cas9-mediated genome editing. Trends Genet 37:639\u2013656. https:\/\/doi.org\/10.1016\/j.tig.2021.02.008","journal-title":"Trends Genet"},{"key":"1161_CR96","doi-asserted-by":"crossref","unstructured":"Beneke T, Gluenz E (2019) LeishGEdit: a method for rapid gene knockout and tagging using CRISPR-Cas9. pp 189\u2013210","DOI":"10.1007\/978-1-4939-9210-2_9"},{"key":"1161_CR97","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijpddr.2018.03.004","volume":"8","author":"C Fernandez-Prada","year":"2018","unstructured":"Fernandez-Prada C, Sharma M, Plourde M et al (2018) High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms. Int J Parasitol Drugs Drug Resist 8:165\u2013173. https:\/\/doi.org\/10.1016\/j.ijpddr.2018.03.004","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"1161_CR98","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01788-17","author":"LC Soares Medeiros","year":"2017","unstructured":"Soares Medeiros LC, South L, Peng D et al (2017) Rapid, selection-free, high-efficiency genome editing in protozoan parasites using CRISPR-Cas9 ribonucleoproteins. MBio. https:\/\/doi.org\/10.1128\/mBio.01788-17","journal-title":"MBio"},{"key":"1161_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.623278","author":"R Yadavalli","year":"2021","unstructured":"Yadavalli R, Umeda K, Waugh HA et al (2021) CRISPR\/Cas9 ribonucleoprotein-based genome editing methodology in the marine protozoan parasite Perkinsus marinus. Front Bioeng Biotechnol. https:\/\/doi.org\/10.3389\/fbioe.2021.623278","journal-title":"Front Bioeng Biotechnol"},{"key":"1161_CR100","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1007\/s00253-018-8927-3","volume":"102","author":"M Grzybek","year":"2018","unstructured":"Grzybek M, Golonko A, G\u00f3rska A et al (2018) The CRISPR\/Cas9 system sheds new lights on the biology of protozoan parasites. Appl Microbiol Biotechnol 102:4629\u20134640. https:\/\/doi.org\/10.1007\/s00253-018-8927-3","journal-title":"Appl Microbiol Biotechnol"},{"key":"1161_CR101","doi-asserted-by":"crossref","unstructured":"Kirti A, Sharma M, Rani K, Bansal A (2021) CRISPRing protozoan parasites to better understand the biology of diseases. pp 21\u201368","DOI":"10.1016\/bs.pmbts.2021.01.004"},{"key":"1161_CR102","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/cmi.12456","volume":"17","author":"L Sollelis","year":"2015","unstructured":"Sollelis L, Ghorbal M, MacPherson CR et al (2015) First efficient CRISPR-Cas9-mediated genome editing in L eishmania parasites. Cell Microbiol 17:1405\u20131412. https:\/\/doi.org\/10.1111\/cmi.12456","journal-title":"Cell Microbiol"},{"key":"1161_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4635605","volume":"2017","author":"D Martel","year":"2017","unstructured":"Martel D, Beneke T, Gluenz E et al (2017) Characterisation of casein kinase 1.1 in Leishmania donovani using the CRISPR Cas9 toolkit. BioMed Res Int 2017:1\u201311. https:\/\/doi.org\/10.1155\/2017\/4635605","journal-title":"BioMed Res Int"},{"key":"1161_CR104","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00340-16","author":"W-W Zhang","year":"2017","unstructured":"Zhang W-W, Lypaczewski P, Matlashewski G (2017) Optimized CRISPR-Cas9 genome editing for Leishmania and its use to target a multigene family, induce chromosomal translocation, and study DNA break repair mechanisms. mSphere. https:\/\/doi.org\/10.1128\/mSphere.00340-16","journal-title":"mSphere"},{"key":"1161_CR105","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S1286-4579(00)01331-9","volume":"2","author":"S Kamhawi","year":"2000","unstructured":"Kamhawi S (2000) The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of infections. Microbes Infect 2:1765\u20131773. https:\/\/doi.org\/10.1016\/S1286-4579(00)01331-9","journal-title":"Microbes Infect"},{"key":"1161_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192723","volume":"13","author":"A Ishemgulova","year":"2018","unstructured":"Ishemgulova A, Hlav\u00e1\u010dov\u00e1 J, Majerov\u00e1 K et al (2018) CRISPR\/Cas9 in Leishmania mexicana: a case study of LmxBTN1. PLoS ONE 13:e0192723. https:\/\/doi.org\/10.1371\/journal.pone.0192723","journal-title":"PLoS ONE"},{"key":"1161_CR107","first-page":"78","volume":"14","author":"G Salehi Sangani","year":"2019","unstructured":"Salehi Sangani G, Jajarmi V, Khamesipour A et al (2019) Generation of a CRISPR\/Cas9-Based Vector Specific for Gene Manipulation in Leishmania major. Iran J Parasitol 14:78\u201388","journal-title":"Iran J Parasitol"},{"key":"1161_CR108","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01941-19","author":"I Louradour","year":"2019","unstructured":"Louradour I, Ghosh K, Inbar E, Sacks DL (2019) CRISPR\/Cas9 mutagenesis in Phlebotomus papatasi: the immune deficiency pathway impacts vector competence for Leishmania major. MBio. https:\/\/doi.org\/10.1128\/mBio.01941-19","journal-title":"MBio"},{"key":"1161_CR109","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev.biochem.78.082307.091526","volume":"78","author":"FE Reyes-Turcu","year":"2009","unstructured":"Reyes-Turcu FE, Ventii KH, Wilkinson KD (2009) Regulation and cellular roles of Ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 78:363\u2013397. https:\/\/doi.org\/10.1146\/annurev.biochem.78.082307.091526","journal-title":"Annu Rev Biochem"},{"key":"1161_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008455","volume":"16","author":"A Damianou","year":"2020","unstructured":"Damianou A, Burge RJ, Catta-Preta CMC et al (2020) Essential roles for deubiquitination in Leishmania life cycle progression. PLoS Pathog 16:e1008455. https:\/\/doi.org\/10.1371\/journal.ppat.1008455","journal-title":"PLoS Pathog"},{"key":"1161_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008828","volume":"16","author":"JD Damasceno","year":"2020","unstructured":"Damasceno JD, Reis-Cunha J, Crouch K et al (2020) Conditional knockout of RAD51-related genes in Leishmania major reveals a critical role for homologous recombination during genome replication. PLoS Genet 16:e1008828. https:\/\/doi.org\/10.1371\/journal.pgen.1008828","journal-title":"PLoS Genet"},{"key":"1161_CR112","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00809-21","author":"GL Turra","year":"2021","unstructured":"Turra GL, Liedgens L, Sommer F et al (2021) In vivo structure-function analysis and redox interactomes of Leishmania tarentolae Erv. Microbiol Spectr. https:\/\/doi.org\/10.1128\/Spectrum.00809-21","journal-title":"Microbiol Spectr"},{"key":"1161_CR113","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1038\/s41467-020-17154-z","volume":"11","author":"W-W Zhang","year":"2020","unstructured":"Zhang W-W, Karmakar S, Gannavaram S et al (2020) A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nat Commun 11:3461. https:\/\/doi.org\/10.1038\/s41467-020-17154-z","journal-title":"Nat Commun"},{"key":"1161_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00468","author":"R Sharma","year":"2020","unstructured":"Sharma R, Silveira-Mattos PS, Ferreira VC et al (2020) Generation and characterization of a dual-reporter transgenic Leishmania braziliensis line expressing eGFP and luciferase. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2019.00468","journal-title":"Front Cell Infect Microbiol"},{"key":"1161_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.105281","volume":"161","author":"S Ebrahimi","year":"2021","unstructured":"Ebrahimi S, Kalantari M, Alipour H et al (2021) In vitro evaluation of CRISPR PX-LmGP63 vector effect on pathogenicity of Leishmania major as a primary step to control leishmaniasis. Microb Pathog 161:105281. https:\/\/doi.org\/10.1016\/j.micpath.2021.105281","journal-title":"Microb Pathog"},{"key":"1161_CR116","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.112965","author":"S Ebrahimi","year":"2021","unstructured":"Ebrahimi S, Alipour H, Azizi K, Kalantari M (2021) Construction of PX-LmGP63 Using CRISPR-Cas9 as primary goal for GP63 gene knockout in Leishmania major and Leishmanization. Jundishapur J Microbiol. https:\/\/doi.org\/10.5812\/jjm.112965","journal-title":"Jundishapur J Microbiol"},{"key":"1161_CR117","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41541-022-00449-1","volume":"7","author":"G Volpedo","year":"2022","unstructured":"Volpedo G, Pacheco-Fernandez T, Holcomb EA et al (2022) Centrin-deficient Leishmania mexicana confers protection against new world cutaneous leishmaniasis. NPJ Vaccines 7:32. https:\/\/doi.org\/10.1038\/s41541-022-00449-1","journal-title":"NPJ Vaccines"},{"key":"1161_CR118","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","volume":"14","author":"E Handman","year":"2001","unstructured":"Handman E (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14:229\u2013243. https:\/\/doi.org\/10.1128\/CMR.14.2.229-243.2001","journal-title":"Clin Microbiol Rev"},{"key":"1161_CR119","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4103\/0974-777X.62881","volume":"2","author":"L Kedzierski","year":"2010","unstructured":"Kedzierski L (2010) Leishmaniasis vaccine: Where are we today? J Glob Infect Dis 2:177. https:\/\/doi.org\/10.4103\/0974-777X.62881","journal-title":"J Glob Infect Dis"},{"key":"1161_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/genes11101159","volume":"11","author":"V Adaui","year":"2020","unstructured":"Adaui V, Kr\u00f6ber-Boncardo C, Brinker C et al (2020) Application of CRISPR\/Cas9-based reverse genetics in Leishmania braziliensis: conserved roles for HSP100 and HSP23. Genes 11:1159. https:\/\/doi.org\/10.3390\/genes11101159","journal-title":"Genes"},{"key":"1161_CR121","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3390\/pathogens11040431","volume":"11","author":"G Volpedo","year":"2022","unstructured":"Volpedo G, Bhattacharya P, Gannavaram S et al (2022) The history of live attenuated centrin gene-deleted Leishmania vaccine candidates. Pathogens 11:431. https:\/\/doi.org\/10.3390\/pathogens11040431","journal-title":"Pathogens"},{"key":"1161_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00408","author":"FH Jesus-Santos","year":"2020","unstructured":"Jesus-Santos FH, Lobo-Silva J, Ramos PIP et al (2020) LPG2 gene duplication in Leishmania infantum: a case for CRISPR-Cas9 gene editing. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2020.00408","journal-title":"Front Cell Infect Microbiol"},{"key":"1161_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.790418","author":"R Sharma","year":"2022","unstructured":"Sharma R, Avenda\u00f1o Rangel F, Reis-Cunha JL et al (2022) Targeted deletion of centrin in Leishmania braziliensis using CRISPR-Cas9-based editing. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2021.790418","journal-title":"Front Cell Infect Microbiol"},{"key":"1161_CR124","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1039\/D1MD00362C","volume":"13","author":"AC Pinheiro","year":"2022","unstructured":"Pinheiro AC, de Souza MVN (2022) Current leishmaniasis drug discovery. RSC Med Chem 13:1029\u20131043. https:\/\/doi.org\/10.1039\/D1MD00362C","journal-title":"RSC Med Chem"},{"key":"1161_CR125","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/acsinfecdis.0c00857","volume":"7","author":"CR Espada","year":"2021","unstructured":"Espada CR, Albuquerque-Wendt A, Hornillos V et al (2021) Ros3 (Lem3p\/CDC50) gene dosage is implicated in miltefosine susceptibility in Leishmania (Viannia) braziliensis clinical isolates and in Leishmania (Leishmania) major. ACS Infect Dis 7:849\u2013858. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00857","journal-title":"ACS Infect Dis"},{"key":"1161_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/571242","volume":"2011","author":"AK Haldar","year":"2011","unstructured":"Haldar AK, Sen P, Roy S (2011) Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int 2011:1\u201323. https:\/\/doi.org\/10.4061\/2011\/571242","journal-title":"Mol Biol Int"},{"key":"1161_CR127","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1093\/cid\/ciaa1236","volume":"72","author":"J-E Potvin","year":"2021","unstructured":"Potvin J-E, Leprohon P, Queffeulou M et al (2021) Mutations in an aquaglyceroporin as a proven marker of antimony clinical resistance in the parasite Leishmania donovani. Clin Infect Dis 72:e526\u2013e532. https:\/\/doi.org\/10.1093\/cid\/ciaa1236","journal-title":"Clin Infect Dis"},{"key":"1161_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.772311","author":"CR Espada","year":"2021","unstructured":"Espada CR, Quilles JC, Albuquerque-Wendt A et al (2021) Effective genome editing in Leishmania (Viannia) braziliensis stably expressing Cas9 and T7 RNA polymerase. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2021.772311","journal-title":"Front Cell Infect Microbiol"},{"key":"1161_CR129","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301665R","author":"N Baron","year":"2024","unstructured":"Baron N, Purushotham R, Pullaiahgari D et al (2024) LeishIF4E2 is a cap\u2010binding protein that plays a role in Leishmania cell cycle progression. FASEB J. https:\/\/doi.org\/10.1096\/fj.202301665R","journal-title":"FASEB J"},{"key":"1161_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008352","volume":"15","author":"N Baron","year":"2021","unstructured":"Baron N, Tupperwar N, Dahan I et al (2021) Distinct features of the Leishmania cap-binding protein LeishIF4E2 revealed by CRISPR-Cas9 mediated hemizygous deletion. PLoS Negl Trop Dis 15:e0008352. https:\/\/doi.org\/10.1371\/journal.pntd.0008352","journal-title":"PLoS Negl Trop Dis"},{"key":"1161_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010364","volume":"18","author":"AJ Roberts","year":"2022","unstructured":"Roberts AJ, Ong HB, Clare S et al (2022) Systematic identification of genes encoding cell surface and secreted proteins that are essential for in vitro growth and infection in Leishmania donovani. PLoS Pathog 18:e1010364. https:\/\/doi.org\/10.1371\/journal.ppat.1010364","journal-title":"PLoS Pathog"},{"key":"1161_CR132","doi-asserted-by":"publisher","first-page":"8139","DOI":"10.3390\/ijms23158139","volume":"23","author":"MM Aldfer","year":"2022","unstructured":"Aldfer MM, AlSiari TA, Elati HAA et al (2022) Nucleoside transport and nucleobase uptake null mutants in Leishmania mexicana for the routine expression and characterization of purine and pyrimidine transporters. Int J Mol Sci 23:8139. https:\/\/doi.org\/10.3390\/ijms23158139","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1161_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043144","volume":"24","author":"MA Ungogo","year":"2023","unstructured":"Ungogo MA (2023) Cloning and characterization of Trypanosoma congolense and T. vivax nucleoside transporters reveal the potential of P1-type carriers for the discovery of broad-spectrum nucleoside-based therapeutics against animal African trypanosomiasis. Int J Mol Sci 24(4):3144. https:\/\/doi.org\/10.3390\/ijms24043144","journal-title":"Int J Mol Sci"},{"key":"1161_CR134","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41467-024-55538-7","volume":"16","author":"A Albuquerque-Wendt","year":"2025","unstructured":"Albuquerque-Wendt A, McCoy C, Neish R et al (2025) Transleish: identification of membrane transporters essential for survival of intracellular Leishmania parasites in a systematic gene deletion screen. Nat Commun 16:299. https:\/\/doi.org\/10.1038\/s41467-024-55538-7","journal-title":"Nat Commun"},{"key":"1161_CR135","doi-asserted-by":"publisher","DOI":"10.1128\/mspheredirect.00340-17","author":"S Chadha","year":"2017","unstructured":"Chadha S, Mallampudi NA, Mohapatra DK, Madhubala R (2017) Genetic validation of Leishmania donovani lysyl-tRNA synthetase shows that it is indispensable for parasite growth and infectivity. mSphere. https:\/\/doi.org\/10.1128\/mspheredirect.00340-17","journal-title":"mSphere"},{"key":"1161_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.988688","author":"EA Alpizar-Sosa","year":"2022","unstructured":"Alpizar-Sosa EA, Kumordzi Y, Wei W et al (2022) Genome deletions to overcome the directed loss of gene function in Leishmania. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2022.988688","journal-title":"Front Cell Infect Microbiol"},{"key":"1161_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed7110384","volume":"7","author":"K Paulini","year":"2022","unstructured":"Paulini K, Lypaczewski P, Zhang W-W et al (2022) Investigating the Leishmania donovani sacp gene and its role in macrophage infection and survival in mice. Trop Med Infect Dis 7:384. https:\/\/doi.org\/10.3390\/tropicalmed7110384","journal-title":"Trop Med Infect Dis"},{"key":"1161_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104378","volume":"86","author":"JBT Carnielli","year":"2022","unstructured":"Carnielli JBT, Dave A, Romano A et al (2022) 3\u2032Nucleotidase\/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine. EBioMedicine 86:104378. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104378","journal-title":"EBioMedicine"},{"key":"1161_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbiopara.2020.111336","volume":"241","author":"GL Turra","year":"2021","unstructured":"Turra GL, Schneider L, Liedgens L, Deponte M (2021) Testing the CRISPR-Cas9 and glmS ribozyme systems in Leishmania tarentolae. Mol Biochem Parasitol 241:111336. https:\/\/doi.org\/10.1016\/j.molbiopara.2020.111336","journal-title":"Mol Biochem Parasitol"},{"key":"1161_CR140","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00861-15","author":"W-W Zhang","year":"2015","unstructured":"Zhang W-W, Matlashewski G (2015) Crispr-cas9-mediated genome editing in Leishmania donovani. MBio. https:\/\/doi.org\/10.1128\/mBio.00861-15","journal-title":"MBio"},{"key":"1161_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176240","volume":"21","author":"A Kantor","year":"2020","unstructured":"Kantor A, McClements M, MacLaren R (2020) CRISPR-Cas9 DNA base-editing and prime-editing. Int J Mol Sci 21:6240. https:\/\/doi.org\/10.3390\/ijms21176240","journal-title":"Int J Mol Sci"},{"key":"1161_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/biology12070997","volume":"12","author":"H Satam","year":"2023","unstructured":"Satam H, Joshi K, Mangrolia U et al (2023) Next-generation sequencing technology: current trends and advancements. Biology 12:997. https:\/\/doi.org\/10.3390\/biology12070997","journal-title":"Biology"}],"container-title":["Acta Parasitologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-025-01161-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11686-025-01161-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-025-01161-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:02:08Z","timestamp":1779357728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11686-025-01161-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":142,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1161"],"URL":"https:\/\/doi.org\/10.1007\/s11686-025-01161-5","relation":{},"ISSN":["1230-2821","1896-1851"],"issn-type":[{"value":"1230-2821","type":"print"},{"value":"1896-1851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human or Animal Rights"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"217"}}